Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with type 1 diabetes mellitus

Muhammad M. Hafiz, Raffaella Poggioli, Aileen Caulfield, Shari Messinger, Milene C. Geiger, David Baidal, Tatiana Froud, Jacqueline V. Ferreira, Andreas G. Tzakis, Camillo Ricordi, Rodolfo Alejandro

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) serological status of transplant donors and recipients has important implications on antiviral prophylaxis, morbidity/mortality, donor selection and hospital stay. We evaluated CMV prevalence in our islet transplant candidates (ITC) in comparison with organ donors. We correlated the CMV serological status of our ITC with serology for Epstein-Barr virus and Parvovirus B19, auto-antibodies, patient's age, age at DM onset, duration of DM, gender, race, ABO group, HLA haplotype and C-peptide levels. Cytomegalovirus transmission after islet transplant using the Edmonton regimen was also evaluated. Cytomegalovirus seropositivity varied according to patient group, age, gender and race. Type 1 DM patients had reduced odds of CMV seropositivity when compared with organ donors. In all groups studied, older patients, females, and non-Caucasians were more likely to be CMV seropositive. In addition, no CMV reactivation, infection or disease was observed among our transplanted patients using this steroid-free regimen even after donor/recipient CMV mismatch.

Original languageEnglish
Pages (from-to)1697-1702
Number of pages6
JournalAmerican Journal of Transplantation
Volume4
Issue number10
DOIs
StatePublished - Oct 1 2004

Fingerprint

Cytomegalovirus
Type 1 Diabetes Mellitus
Allografts
Transplants
Tissue Donors
HLA-C Antigens
Donor Selection
Parvovirus
C-Peptide
Cytomegalovirus Infections
Serology
Human Herpesvirus 4
Age of Onset
Haplotypes
Antiviral Agents
Length of Stay
Age Groups
Steroids
Morbidity
Mortality

Keywords

  • Cytomegalovirus
  • Islet transplant
  • Type 1 diabetes mellitus

ASJC Scopus subject areas

  • Immunology

Cite this

Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with type 1 diabetes mellitus. / Hafiz, Muhammad M.; Poggioli, Raffaella; Caulfield, Aileen; Messinger, Shari; Geiger, Milene C.; Baidal, David; Froud, Tatiana; Ferreira, Jacqueline V.; Tzakis, Andreas G.; Ricordi, Camillo; Alejandro, Rodolfo.

In: American Journal of Transplantation, Vol. 4, No. 10, 01.10.2004, p. 1697-1702.

Research output: Contribution to journalArticle

Hafiz, Muhammad M. ; Poggioli, Raffaella ; Caulfield, Aileen ; Messinger, Shari ; Geiger, Milene C. ; Baidal, David ; Froud, Tatiana ; Ferreira, Jacqueline V. ; Tzakis, Andreas G. ; Ricordi, Camillo ; Alejandro, Rodolfo. / Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with type 1 diabetes mellitus. In: American Journal of Transplantation. 2004 ; Vol. 4, No. 10. pp. 1697-1702.
@article{1bea6020f5974c749631052f37b6ae01,
title = "Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with type 1 diabetes mellitus",
abstract = "Cytomegalovirus (CMV) serological status of transplant donors and recipients has important implications on antiviral prophylaxis, morbidity/mortality, donor selection and hospital stay. We evaluated CMV prevalence in our islet transplant candidates (ITC) in comparison with organ donors. We correlated the CMV serological status of our ITC with serology for Epstein-Barr virus and Parvovirus B19, auto-antibodies, patient's age, age at DM onset, duration of DM, gender, race, ABO group, HLA haplotype and C-peptide levels. Cytomegalovirus transmission after islet transplant using the Edmonton regimen was also evaluated. Cytomegalovirus seropositivity varied according to patient group, age, gender and race. Type 1 DM patients had reduced odds of CMV seropositivity when compared with organ donors. In all groups studied, older patients, females, and non-Caucasians were more likely to be CMV seropositive. In addition, no CMV reactivation, infection or disease was observed among our transplanted patients using this steroid-free regimen even after donor/recipient CMV mismatch.",
keywords = "Cytomegalovirus, Islet transplant, Type 1 diabetes mellitus",
author = "Hafiz, {Muhammad M.} and Raffaella Poggioli and Aileen Caulfield and Shari Messinger and Geiger, {Milene C.} and David Baidal and Tatiana Froud and Ferreira, {Jacqueline V.} and Tzakis, {Andreas G.} and Camillo Ricordi and Rodolfo Alejandro",
year = "2004",
month = "10",
day = "1",
doi = "10.1111/j.1600-6143.2004.00557.x",
language = "English",
volume = "4",
pages = "1697--1702",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with type 1 diabetes mellitus

AU - Hafiz, Muhammad M.

AU - Poggioli, Raffaella

AU - Caulfield, Aileen

AU - Messinger, Shari

AU - Geiger, Milene C.

AU - Baidal, David

AU - Froud, Tatiana

AU - Ferreira, Jacqueline V.

AU - Tzakis, Andreas G.

AU - Ricordi, Camillo

AU - Alejandro, Rodolfo

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Cytomegalovirus (CMV) serological status of transplant donors and recipients has important implications on antiviral prophylaxis, morbidity/mortality, donor selection and hospital stay. We evaluated CMV prevalence in our islet transplant candidates (ITC) in comparison with organ donors. We correlated the CMV serological status of our ITC with serology for Epstein-Barr virus and Parvovirus B19, auto-antibodies, patient's age, age at DM onset, duration of DM, gender, race, ABO group, HLA haplotype and C-peptide levels. Cytomegalovirus transmission after islet transplant using the Edmonton regimen was also evaluated. Cytomegalovirus seropositivity varied according to patient group, age, gender and race. Type 1 DM patients had reduced odds of CMV seropositivity when compared with organ donors. In all groups studied, older patients, females, and non-Caucasians were more likely to be CMV seropositive. In addition, no CMV reactivation, infection or disease was observed among our transplanted patients using this steroid-free regimen even after donor/recipient CMV mismatch.

AB - Cytomegalovirus (CMV) serological status of transplant donors and recipients has important implications on antiviral prophylaxis, morbidity/mortality, donor selection and hospital stay. We evaluated CMV prevalence in our islet transplant candidates (ITC) in comparison with organ donors. We correlated the CMV serological status of our ITC with serology for Epstein-Barr virus and Parvovirus B19, auto-antibodies, patient's age, age at DM onset, duration of DM, gender, race, ABO group, HLA haplotype and C-peptide levels. Cytomegalovirus transmission after islet transplant using the Edmonton regimen was also evaluated. Cytomegalovirus seropositivity varied according to patient group, age, gender and race. Type 1 DM patients had reduced odds of CMV seropositivity when compared with organ donors. In all groups studied, older patients, females, and non-Caucasians were more likely to be CMV seropositive. In addition, no CMV reactivation, infection or disease was observed among our transplanted patients using this steroid-free regimen even after donor/recipient CMV mismatch.

KW - Cytomegalovirus

KW - Islet transplant

KW - Type 1 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=4744359046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4744359046&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2004.00557.x

DO - 10.1111/j.1600-6143.2004.00557.x

M3 - Article

C2 - 15367227

AN - SCOPUS:4744359046

VL - 4

SP - 1697

EP - 1702

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 10

ER -